The most recognized biological effect of paclitaxel formulated with CrEL is an acute hypersensitivity reaction, characterized by dyspnea, flushing, rash, chest pain, tachycardia, hypotension, angioedema, and generalized urticaria.
Positions and Honors Positions and Employment 1985-1986 Research Associate, Pathology Department, Hahnemann Hospital, Philadelphia, PA 1986-1987 Internship (Medical), St. Agnes Hospital, Caton and Wilkens Avenue, Baltimore, MD 1987-1989 Residency (Medical), St. Agnes Hospital, Caton and Wilkens Avenue, Baltimore, MD 1989-1992 Fellowship (Hematology/Oncology), University of Maryland Cancer Center, 22 South Greene Street, Baltimore, MD Assistant Instructor, University of Maryland School of Medicine, Department of Medicine, University of Maryland Cancer Center 1990-1992 Recipient of the American Cancer Society Clinical Oncology Fellowship Abraxis EX2001 Apotex Inc. and Apotex Corp. v. Abraxis Bioscience, LLC
Breast Cancer Research and Treatment 111, 355-364. b. Tkaczuk KH, Tait NS Ioffe O, Tan M, Goloubeva OG, Lesko SA, Deamond SF, Zhou D, Lum ZP, Sutula MJ, Van Echo D and Ts’o PO.
We found that GP-88 is a negative prognostic marker in BC patients with hormone sensitive cancer, which may be independent of Her2; additionally, overexpression of GP-88 may render BC tumors resistant to anti Her2 therapy with trastuzumab.
Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.